Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show ...

March 11, 2025 Barclays 27th Annual Global Healthcare Conference, Miami Beach, FL Fireside chat: March 12, 2025, from ...

A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

Learn more about whether AbbVie Inc. or BeiGene, Ltd. is a better investment based on AAII's A+ Investor grades, which ...

Learn more about whether Insmed Incorporated or BeiGene, Ltd. is a better investment based on AAII's A+ Investor grades, ...

Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated CLL patients, click for more on NRIX.

ON THE UP: Owen Bruton's game has taken another big step forward this season at Hull Seahawks. Picture: Adam Everitt/Seahawks Media. To buy tickets for Sunday’s Yorkshire derby clash between ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...